Company news
Arovella Therapeutics Limited (ASX:ALA) news
Arovella Therapeutics Limited news releases on 6ix. Latest, Oct 6, 2026: Second Clinical Batch Released for Immediate Patient Use
Press releases & updates
Second Clinical Batch Released for Immediate Patient Use
October 6, 2026
The path to first patient dosing
October 1, 2026
Clinical manufacturing batch released, first site activated
September 6, 2026
Arovella Appoints Acting CEO
May 6, 2026
Board Refresh and CEO Resignation
May 4, 2026
CLDN18.2 CAR iNKT Cell Preclinical Data Update
March 31, 2026
Half Year Report and Appendix 4D
February 19, 2026
ALA's IND FOR ALA-101 ACCEPTED BY THE U.S.FDA
January 28, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 22, 2026
Arovella Therapeutics : appoints former CSL CSO Dr Andrew Nash as Non-executive Director
November 11, 2025
Positive FDA Type D Meeting Outcome
October 27, 2025
CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
October 2, 2025
Arovella receives R&D tax rebate of $3.21 million
September 22, 2025
S&P DJI Announces September 2025 Quarterly Rebalance
September 5, 2025
Appendix 4E and Annual Report
August 21, 2025
S&P DJI Announces March 2025 Quarterly Rebalance
March 7, 2025
Research Agreement with University of North Carolina
March 3, 2025
Reinstatement to Official Quotation
February 25, 2025
Prospectus
February 25, 2025
Arovella $15m Placement to fund Phase 1
February 25, 2025
Voluntary Suspension
February 9, 2025
Trading Halt
February 5, 2025
Arovella $20m Placement - fully funded to complete Phase 1
January 9, 2025
Arovella receives R&D tax rebate of $3.0 million
October 25, 2024
Positive pre-IND feedback from FDA for ALA-101
August 6, 2024
Zolpimist Update
June 12, 2024
Arovella completes manufacturing scale-up
June 4, 2024
Arovella Completes $12.5M Placement - Funded to Phase 1 Data
March 25, 2024
Pause in Trading
March 21, 2024
Appendix 4D and Half Year Report
February 28, 2024
Arovella licenses novel CAR-iNKT cell armouring technology
January 29, 2024
Arovella receives R&D tax credit of $1.94 million
November 20, 2023
Arovella licenses novel solid tumour targeting technology
October 11, 2023
Reinstatement to Quotation
October 11, 2023
Suspension from Quotation
October 11, 2023
Response to ASX Price Query
August 30, 2023
Quarterly Appendix 4C and Activities Report
July 24, 2023
Completion of oversubscribed Share Purchase Plan (SPP)
July 10, 2023
Share Purchase Plan (SPP) Closing Date Extended
June 28, 2023
Share Purchase Plan (SPP) Offer Booklet
June 14, 2023
AROVELLA COMPLETES $4M PLACEMENT & LAUNCHES $1M SPP
June 7, 2023
Arovellas OroMist R&D facility closure completed
May 1, 2023
Response to ASX Query
April 26, 2023
Response to ASX Aware Query
April 20, 2023
ALA-101 confers survival benefit in leukemia model
April 16, 2023
AROVELLA COMPLETES $1.65M PLACEMENT
January 18, 2023
R&D Tax Incentive refund received
November 29, 2022
Europe Patent granted for iNKT Cell Therapy Platform
November 6, 2022
Arovella to close its Perth OroMist R&D Facility
October 25, 2022
Preclinical trial of ALA iNKT therapy and IMU onCARlytics
September 26, 2022